STAT3 and breast cancer: While there remains a plethora of preclinical studies analyzing IL-6/JAK/STAT3 inhibitors on breast cancer growth, there remains an urgent gap analyzing compound efficacy against breast cancer metastases in vivo. Additionally, since IL-6 modulates multiple physiological processes and oncogenic pathways, elucidating effective biomarkers for breast cancer patients who could benefit from targeted IL-6/JAK/STAT3 inhibitors could aid in the development of therapeutics for metastatic breast cancer patients.